What's Going to Be Hot at AHA 2023

Buzz is building for SELECT, the semaglutide CV outcomes trial, and ORBITA-2, a sham-controlled trial of PCI in stable CAD.

Related Keywords

Nigeria ,Philadelphia ,Pennsylvania ,United States ,Dallas ,Texas ,American ,Laura Mckeown ,Los Angeles ,Amit Khera ,Lilly Dicerna Pharma ,Joanna Chikwe ,Todd Neale ,Michael Oriordan ,Bayer Janssen ,Health Innovation Pavilion ,Bristol Myers Squibb ,National Heart ,Astrazeneca ,Population Health ,Novo Nordisk ,Blood Institute Tiffany Powell Wiley ,Sinai Medical Center ,Md Ut Southwestern Medical Center ,American Heart Association ,Medical Center ,Cedars Sinai Medical Center ,Blood Institute ,Tiffany Powell Wiley ,Achieving Equity ,China Rural Hypertension Control Project ,Anthos Therapeutics ,Dicerna Pharma ,Michaelo Riordan ,